Capital Increase from Authorized Capital Resolved and placement of the 2020 perpetual bond resolved, as well as commitment to repurchase the 2020 bond
The Management Board of MEDIQON Group AG (ISIN: DE0006618309) today resolved, with the approval of the Supervisory Board, to carry out a capital increase with the exclusion of subscription rights by issuing new shares against cash contributions using part of the authorized capital (up to EUR 432,666.00). The new ordinary bearer shares (no-par value shares) will be offered exclusively to selected professional investors in a private placement. The issue price was set at EUR 14.60 per new share.
In addition, the Management Board of MEDIQON Group AG today resolved, with the approval of the Supervisory Board, the placement of bearer bonds held by the Company itself from the 2020 bond issue (ISIN: DE000A254TL0) in the nominal amount of EUR 12.5 million. The bearer bonds will be placed in a private placement at an issue price of 77.2% of the nominal value.
In total, the Company plans to record a cash inflow of approximately EUR 16 million.
MEDIQON Group AG has also committed to an anchor investor of the bond to conduct one or more public cash buyback offers with respect to up to all bearer bonds from the 2020 bond (ISIN: DE000A254TL0) within the next two years, provided the Company has excess liquidity available for the buyback. Furthermore, the Company intends to make a repurchase offer in shares at an issue price of at least EUR 18.00 per share for all bearer bonds for which no cash repurchase offer has been made within two years.